ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: Perrigo Co. Plc (PRGO) Report Updated: Oct 21, 2017 | Print This Page

Get more stock ratings by Louis Navellier

Perrigo Co. Plc (PRGO)

Rating: Sell Volatility: Conservative
Total Grade: D Industry: Pharmaceuticals
Competitors: OPNT,JNJ,MYOK,SNY

Stock Analysis

Rating: Monthly View

A
B
C
D
F
October November December January February March April May June July August September

Rating: Weekly View

This Week: D down downgrade
Last Week: C same upgrade
Two Weeks Ago: D up no change
service keys

Perrigo Co. Plc© quotemedia

Company Profile

Perrigo Company plc, through its subsidiaries, develops, manufactures, and markets over-the-counter (OTC) consumer goods and pharmaceutical products worldwide. The company operates through Consumer Healthcare (CHC), Branded Consumer Healthcare (BCH), Prescription Pharmaceuticals (Rx Pharmaceuticals), Specialty Sciences, and Other segments. The CHC segment offers OTC products, including analgesics, cough/cold/allergy/sinus, gastrointestinal, infant nutritional, smoking cessation, animal health, feminine hygiene, diabetes and dermatological care, diagnostic, and other healthcare products, as well as vitamins, minerals, and dietary supplements; and contract manufacturing services. It serves retail drug, supermarket, mass merchandise chains, and wholesalers through sales force and industry brokers. The BCH segment provides branded OTC products in the natural health; vitamins, minerals, and supplements; cough, cold, and allergy; personal care and derma-therapeutics; lifestyle; and anti-parasite areas. This segment serves pharmacies, drug, and grocery stores through pharmacy sales force, as well as a network of pharmacists. The Rx Pharmaceuticals segment offers generic and specialty pharmaceutical prescription drugs in various dosage forms, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions, powders, controlled substances, injectables, hormones, women's health products, oral solid dosage forms, and oral liquid formulations; and ORx products. It serves wholesalers; retail drug, supermarket, and mass merchandise chains; hospitals; and pharmacies. The Specialty Sciences segment provides Tysabri to treat multiple sclerosis. The Other segment offers active pharmaceutical ingredients that are used by generic and branded pharmaceutical companies. The company was founded in 1887 and is headquartered in Dublin, Ireland.